Table of Awardees
Biomarker Developmental Laboratory Grantees, Listed Alphabetically by State

Principal Investigator
Grant Number
First Year Award

Focus of Grant


Wilbur Franklin, M.D.
University of Colorado Health Science Center,
Denver, Colo.
five-year grant
$399,741 (first year)

Lung: Use spectral image technology, differential gene expression techniques, and regular genetic and biochemical techniques to assess normal, premalignant, and malignant lung cancer cells to identify and evaluate potential biomarkers. Spectral Imaging,
Carlsbad, Calif.

Lakewood, Colo.

Jose Costa, M.D.
Yale University,
New Haven, Conn.
three-year grant
$396,255 (first year)

Breast, Colon, Pancreas: Perform detailed mutational analysis of specific genes using a variety of technologies and developing a new technology which can detect and quantify point mutations at the cytologic level.  
Marc Lippman, M.D.
Lombardi Cancer Center Washington, D.C.
five-year grant
$245,578 (first year)
Breast: Characterize protein expression profiles in normal breast tissue, ductal carcinoma in situ, and early invasive breast cancer to identify a protein signature associated with invasive cancer and test the feasibility of detecting such a protein easily in accessible body fluids.  
Melvin Tockman, M.D., Ph.D.
University of South Florida,
Tampa, Fla.
five-year grant
$385,069 (first year)
Lung: Evaluate existing and potential biomarkers in archived sputum specimens from a screening trial of smokers and former smokers. Bayer
Emoryville, Calif.
David Fishman, M.D.
Robert H. Lurie Comprehensive Cancer Ctr.
Northwestern University,
Evanston, Ill.
five-year grant
$809,862 (first year)
Ovary: Determine the accurate detection of early rather than
late-stage disease in asymptomatic women at increased risk. Early genetic changes and aberrant MRNA expression will be evaluated as potential biomarkers.
Technologies, Inc.
Irvine, Calif.

Circon Corp.
Santa Barbara, Calif.

David Sidransky, M.D.
Johns Hopkins University, Baltimore, Md.
five-year grant
$599,110 (first year)
Lung: With a focus on non-small cell lung cancer, will identify biomarkers in bronchoalveolar lavage and serum samples from lung cancer patients, to characterize and translate into clinical tests. Will develop cDNA libraries as resource. Research Genetics, Inc.
Huntsville, Ala.

Oncogene Research
Cambridge, Mass.

Zeneca Diagnostics, U.K.

Stephen Meltzer, M.D
University of Maryland, School of Medicine
Baltimore, Md.
five-year grant
$384,646 (first year)
Esophagus: Using the unique molecular alterations that occur during cellular progression to cancer, will develop assays to detect cancer-related proteins for diagnosis, screening, prevention, and treatment.  
Edward Highsmith, Ph.D.
University of Maryland,
School of Medicine
Baltimore, Md.
three-year grant
$382,050 (first year)
Esophagus, Gastrointestinal Tract, and Lung: Measure telomerase activity in non-cellular fluids, such as plasma, in patients with a variety of cancers, and evaluate the utility of plasma telomerase measurements as aids in diagnosis and as a monitoring tool during therapy to predict relapse. Advanced Bioscience
Lab, Inc. Kensington, Md.
Samir Hanash, M.D., Ph.D.
University of Michigan,
Ann Arbor, Mich.
five-year grant
$463,272 (first year)
Colon, Esophagus, Liver, Lung, and Ovary: Identify tumor antigens that induce a humoral response and tumor-secreted proteins and develop assays to test the utility of markers that are found.  
David Beach, Ph.D.
Genetica, Inc.,
Cold Spring Harbor, N.Y.
five-year grant
$446,741 (first year)
Breast and Colon: Create a database of expression patterns for secreted and cell surface proteins in early stage lesions of the breast and colon.  
Yingming Zhao, Ph.D. Mount Sinai School of Medicine
New York, N.Y.
five-year grant
$216,104 (first year)
Ovary and Prostate: Develop protein biomarkers for early diagnosis, risk assessment, and anti-cancer drug evaluation using laser-capture microdissection and mass spectrometry.  
Jeffery Marks, Ph.D.
Duke Medical Center,
Durham, N.C.
five-year grant
$400,000 (first year)
Breast: Identify expression-based markers for breast cancer to detect circulating breast cancer cells. Antibodies will be developed for gene products that may be secreted or presented on the cell surface. Abbott Pharmaceuticals, Chicago, Ill.
Timothy Block, Ph.D.
Thomas Jefferson University,
Philadelphia, Pa.
five-year grant
$327,931 (first year)
Liver: Test for serum polypeptides as potential biomarkers across the disease continuum, using people with liver cancer and those with hepatitis. Oxford Glycosciences,
Wakefield, Mass.
William Bigbee, Ph.D.
University of Pittsburgh,
Pittsburgh, Pa.
five-year grant
$559,290 (first year)
Colon and Lung: Develop assays to detect cancer-related proteins in body fluids and identify gene mutations. Will use SAGE, immunoassay, and PCR-based analysis.  
Bogdan Czerniak, M.D., Ph.D.
University of Texas-
M. D. Anderson,
Houston, Texas
five-year grant
$651,147 (first year)
Bladder: Develop markers for early detection of occult urinary bladder cancer and its progression to invasive and aggressive disease. Create shared database on all tested markers and their performance as diagnostic probes.  
Adi Gazdar, M.D.
University of Texas-Southwestern,
Dallas, Texas
five-year grant
$430,454 (first year)
Lung: Using tumor DNA extracted from plasma, will look for molecular changes. Markers to be studied include onset of clonality, alleleic losses at multiple regions, microsatellite alterations, and the presence of aberrantly methylated genes. Create specimen repository.  
George Wright, Jr., Ph.D.
Eastern Virginia
Medical School
Norfolk, Va.
five-year grant
$345,773 (first year)
Breast and Prostate: Use customized protein chips in proteomic analysis based on Surface Enhanced Laser Ionization/Desorption (SELDI) to identify biomarkers for the detection of prostate and breast cancers at different stages of the progression to cancer.

Biosystems, Inc.
Palo Alto, Calif.

Arcturus Engineering, Inc.
Mountain View,

Nancy Kiviat, M.D. University of Washington,
Seattle, Wash.
five-year grant
$408,070 (first year)
Multiple Sites: Develop assays to detect cancer-related proteins in body fluids and tissues, and determine which secreted proteins correlate with cancerous or precancerous lesions. ORCA Biosciences, Inc.
Seattle, Wash.

Seattle, Wash.

Back to Press Release